D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00

Reviva Pharmaceuticals (NASDAQ:RVPH) had its target price decreased by equities researchers at D. Boral Capital from $8.00 to $3.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. D. Boral Capital’s target price would suggest a potential upside of 237.08% from the stock’s previous close.

Separately, HC Wainwright lowered their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $9.00.

Reviva Pharmaceuticals Stock Up 8.5%

RVPH stock opened at $0.89 on Tuesday. The company has a market cap of $41.60 million, a price-to-earnings ratio of -0.80 and a beta of 0.08. The business has a fifty day simple moving average of $0.83 and a 200-day simple moving average of $1.34. Reviva Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. As a group, analysts expect that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 4th quarter valued at about $36,000. EMC Capital Management increased its holdings in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after acquiring an additional 26,134 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter valued at approximately $25,000. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 311,701 shares of the company’s stock worth $564,000 after purchasing an additional 33,205 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals in the fourth quarter worth $45,000. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.